Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. 2014

Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.

Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.

UI MeSH Term Description Entries
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D006861 Hydrogen Peroxide A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. Hydrogen Peroxide (H2O2),Hydroperoxide,Oxydol,Perhydrol,Superoxol,Peroxide, Hydrogen
D000447 Aldehydes Organic compounds containing a carbonyl group in the form -CHO. Aldehyde
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D061986 MCF-7 Cells An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.) MCF7 Cells,Michigan Cancer Foundation 7 Cells,Cell, MCF-7,Cell, MCF7,Cells, MCF-7,Cells, MCF7,MCF 7 Cells,MCF-7 Cell,MCF7 Cell

Related Publications

Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
March 2018, Journal of inorganic biochemistry,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
June 2007, Toxicology,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
February 2011, Free radical biology & medicine,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
February 2015, Journal of pharmaceutical and biomedical analysis,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
January 2003, Acta medica (Hradec Kralove),
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
May 2012, Chemico-biological interactions,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
November 1999, The Journal of laboratory and clinical medicine,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
November 2015, Biochimica et biophysica acta,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
September 2008, British journal of pharmacology,
Eliška Potůčková, and Kateřina Hrušková, and Jan Bureš, and Petra Kovaříková, and Iva A Špirková, and Kateřina Pravdíková, and Lucie Kolbabová, and Tereza Hergeselová, and Pavlína Hašková, and Hana Jansová, and Miloslav Macháček, and Anna Jirkovská, and Vera Richardson, and Darius J R Lane, and Danuta S Kalinowski, and Des R Richardson, and Kateřina Vávrová, and Tomáš Šimůnek
January 1990, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!